Korean J Urol.  2009 Apr;50(4):311-319.

Can We Use Single Nucleotide Polymorphism and Runt Domain Transcription Factor 3 Methylation as Tumor Markers for Bladder Cancer?

• Kim WJ
• Kim YJ

Abstract

PURPOSE
Although many tumor markers have been evaluated in relation to bladder cancer, none of these biomarkers reported to date has shown sufficient sensitivity and specificity for the detection of the whole spectrum of bladder cancer diseases in routine clinical practice. The limited value of the established prognostic markers requires analysis of new molecular parameters of interest for predicting the prognosis of bladder cancer patients. MATERIALS AND METHODS: We conducted a review of the literature with a focus on recent advances in genetic polymorphism and hypermethylation events in relation to bladder transitional cell carcinoma. RESULTS: Recently, there has been major progress in both genetic polymorphism in relation to bladder cancer and molecular genetic and epigenetic changes leading to the development of transitional cell carcinoma. However, studies on numerous single-nucleotide polymorphisms in relation to bladder cancer have provided only a few genetic polymorphisms with only marginal information on patients' prognosis. For this reason, interest is increasing in epigenetic changes in bladder cancer. The epigenetic silencing of tumor suppressor genes is interesting from a clinical standpoint because of the possibility to reverse the epigenetic changes and thus restore gene function to a cell. Treatment with DNA methylation inhibitors can restore the activities of dormant genes and decrease the growth rate of cancer cells in a heritable fashion. CONCLUSIONS: Epigenetic modification may be possible to partially reverse the cancer phenotype, and this will eventually lead to targeted therapy tailored toward specific molecular therapy in the near future.

Keyword

Urinary bladder neoplasms; Genetic epigenesis; Genetic polymorphism

MeSH Terms

Biomarkers
Carcinoma, Transitional Cell
DNA Methylation
Epigenesis, Genetic
Epigenomics
Genes, Tumor Suppressor
Humans
Molecular Biology
Phenotype
Polymorphism, Genetic
Polymorphism, Single Nucleotide
Prognosis
Sensitivity and Specificity
Transcription Factor 3
Transcription Factors
Biomarkers, Tumor
Urinary Bladder
Urinary Bladder Neoplasms
Transcription Factor 3
Transcription Factors

Reference

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001. 51:15–36.

2. Koss LG. Mapping of the urinary bladder: its impact on the concepts of bladder cancer. Hum Pathol. 1979. 10:533–548.

3. Messing EM. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Urothelial tumors of the bladder. Campbell-Walsh urology. 2007. 9th ed. Philadelphia: Saunders;2407–2446.

4. Al-Sukhun S, Hussain M. Molecular biology of transitional cell carcinoma. Crit Rev Oncol Hematol. 2003. 47:181–193.

5. Ponder BA. Cancer genetics. Nature. 2001. 411:336–341.

6. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000. 16:168–174.

7. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999. 21:163–167.

8. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001. 61:8659–8663.

9. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 2002. 62:4048–4053.

10. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res. 2004. 10:1887–1893.

11. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001. 20:3139–3155.

12. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA. 1998. 95:11891–11896.

13. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A. 1999. 96:12754–12759.

14. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999. 59:71–73.

15. Yoon SJ, Lee SC, Kim WJ. Genotypes of TNF-alpha, VEGF, TGF-beta1, hOGG1, GSTM1 and GSTT1: useful determinants for the clinical outcome of bladder cancer. Korean J Urol. 2004. 46:849–857.

16. Kim WJ, Yoon SJ. Current trend in molecular aspects of bladder cancer. Korean J Urol. 2005. 46:211–220.

17. Shin KH, Lee SC, Kim WJ. Effects of smoking and polymorphisms of glutathione S-transferase M1 and T1 as risk factors on the development of bladder cancer. Korean J Urol. 2002. 43:561–567.

18. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005. 366:649–659.

19. Green J, Banks E, Berrington A, Darby S, Deo H, Newton R. N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer. 2000. 83:412–417.

20. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev. 2000. 9:461–467.

21. Vineis P, Marinelli D, Autrup H, Brockmoller J, Cascorbi I, Daly AK, et al. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev. 2001. 10:1249–1252.

22. Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control. 1997. 8:346–355.

23. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002. 506-507:65–77.

24. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther. 1983. 33:355–359.

25. Sinues B, Perez J, Bernal ML, Saenz MA, Lanuza J, Bartolome M. Urinary mutagenicity and N-acetylation phenotype in textile industry workers exposed to arylamines. Cancer Res. 1992. 52:4885–4889.

26. Kim WJ, Lee HL, Lee SC, Kim YT, Kim H. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol. 2000. 164:209–213.

27. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, et al. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst. 1994. 86:712–716.

28. Seidegard J, Pero RW, Miller DG, Beattie EJ. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis. 1986. 7:751–753.

29. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993. 85:1159–1164.

30. Katoh T, Inatomi H, Kim H, Yang M, Matsumoto T, Kawamoto T. Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. Cancer Lett. 1998. 132:147–152.

31. Ryk C, Berggren P, Kumar R, Hemminki K, Larsson P, Steineck G, et al. Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer. 2005. 113:761–768.

32. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 1996. 56:3915–3925.

33. Kim WJ, Kim H, Kim CH, Lee MS, Oh BR, Lee HM, et al. GSTT1-null genotype is a protective factor against bladder cancer. Urology. 2002. 60:913–918.

34. Sasaki M, Nakajima K, Perinchery G, Fujino T, Oh BR, Fujimoto S, et al. Frequent genotype changes at -308 of the human tumor necrosis factor-alpha promoter region in human uterine endometrial cancer. Oncol Rep. 2000. 7:369–373.

35. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 1998. 91:3574–3581.

36. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993. 143:1255–1262.

37. Li N, Kanda K, Fukumori T, Inoue Y, Nishitani M, Kanayama H, et al. Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer. Urol Oncol. 2000. 6:10–15.

38. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 1995. 55:510–513.

39. Jeong P, Kim EJ, Kim EG, Byun SS, Kim CS, Kim WJ. Association of bladder tumors and GA genotype of -308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression. Urology. 2004. 64:1052–1056.

40. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology. 2005. 65:70–75.

41. Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 1998. 58:1298–1304.

42. Chow NH, Liu HS, Chan SH, Cheng HL, Tzai TS. Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res. 1999. 19:4593–4597.

43. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer. 2000. 82:161–166.

44. Vispe S, Yung TM, Ritchot J, Serizawa H, Satoh MS. A cellular defense pathway regulating transcription through poly (ADP-ribosyl) ation in response to DNA damage. Proc Natl Acad Sci USA. 2000. 97:9886–9891.

45. Cairns J. Aging and cancer as genetic phenomena. Natl Cancer Inst Monogr. 1982. 60:237–239.

46. Knudson AG Jr. The genetic predisposition to cancer. Birth Defects Orig Artic Ser. 1989. 25:15–27.

47. Shields PG, Harris CC. Molecular epidemiology and the genetics of environmental cancer. JAMA. 1991. 266:681–687.

48. Lee YS, Lee HS, Park MK, Hwang ES, Park EM, Kasai H, et al. Identification of 8-hydroxyguanine glycosylase activity in mammalian tissues using 8-hydroxyguanine specific monoclonal antibody. Biochem Biophys Res Commun. 1993. 196:1545–1551.

49. Tchou J, Kasai H, Shibutani S, Chung MH, Laval J, Grollman AP, et al. 8-oxoguanine (8-hydroxyguanine) DNA glycosylase and its substrate specificity. Proc Natl Acad Sci USA. 1991. 88:4690–4694.

50. Klungland A, Rosewell I, Hollenbach S, Larsen E, Daly G, Epe B, et al. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc Natl Acad Sci USA. 1999. 96:13300–13305.

51. De Marzo AM, Marchi VL, Yang ES, Veeraswamy R, Lin X, Nelson WG. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res. 1999. 59:3855–3860.

52. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999. 27:2291–2298.

53. Ohtani-Fujita N, Dryja TP, Rapaport JM, Fujita T, Matsumura S, Ozasa K, et al. Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genet Cytogenet. 1997. 98:43–49.

54. Horikawa Y, Sugano K, Shigyo M, Yamamoto H, Nakazono M, Fujimoto H, et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol. 2003. 169:1541–1545.

55. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 2005. 65:9347–9354.

56. Muto S, Horie S, Takahashi S, Tomita K, Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res. 2000. 60:4021–4025.

57. Kagoshima H, Shigesada K, Satake M, Ito Y, Miyoshi H, Ohki M, et al. The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet. 1993. 9:338–341.

58. Cohen MM Jr. RUNX genes, neoplasia, and cleidocranial dysplasia. Am J Med Genet. 2001. 104:185–188.

59. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene. 2004. 23:4198–4208.

60. Ogawa E, Inuzuka M, Maruyama M, Satake M, Naito-Fujimoto M, Ito Y, et al. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. Virology. 1993. 194:314–331.

61. Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol. 1993. 13:3324–3339.

62. Bae SC, Choi JK. Tumor suppressor activity of RUNX3. Oncogene. 2004. 23:4336–4340.

63. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005. 5:376–387.

64. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997. 278:1059–1064.

65. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell. 1997. 89:773–779.

66. Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, Namba Y, et al. Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian runt domain. Gene. 1995. 159:245–248.

67. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21 (WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol. 2005. 25:8097–8107.

68. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002. 109:113–124.

69. Li QL, Kim HR, Kim WJ, Choi JK, Lee YH, Kim HM, et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun. 2004. 314:223–228.

70. Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol. 2004. 10:376–380.

71. Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004. 84:479–484.

72. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene. 2004. 23:6736–6742.

73. Wada M, Yazumi S, Takaishi S, Hasegawa K, Sawada M, Tanaka H, et al. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene. 2004. 23:2401–2407.

74. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, et al. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem. 1999. 274:31577–31582.

75. Lund AH, van Lohuizen M. RUNX: a trilogy of cancer genes. Cancer Cell. 2002. 1:213–215.

76. Ito Y, Miyazono K. RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev. 2003. 13:43–47.

77. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993. 75:805–816.

78. Malliri A, Yeudall WA, Nikolic M, Crouch DH, Parkinson EK, Ozanne B. Sensitivity to transforming growth factor beta 1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21waf1 induction are important early events. Cell Growth Differ. 1996. 7:1291–1304.

79. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994. 78:59–66.

80. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993. 366:701–704.

81. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001. 29:117–129.

82. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000. 103:295–309.

83. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993. 75:817–825.

84. Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D, Moustakas A. Role of Smad proteins and transcription factor Sp1 in p21 (Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem. 2000. 275:29244–29256.

85. Seoane J, Le HV, Shen L, Anderson SA, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004. 117:211–223.

86. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995. 9:1149–1163.

87. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature. 1997. 389:187–190.

88. Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 2008. 180:1141–1145.

89. Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005. 66(6):Suppl 1. 64–74.

90. Liou LS. Urothelial cancer biomarkers for detection and surveillance. Urology. 2006. 67:25–33.

91. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006. 49:466–475.

92. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998. 72:141–196.

93. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 1995. 81:197–205.

94. Balmain A. Cancer: new-age tumour suppressors. Nature. 2002. 417:235–237.